Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 19Triple Negative Breast Neoplasms 2Cardiotoxicity 2Ovarian Neoplasms 1Obesity 1Inflammation 1Hot Flashes 1Highly Endocrine Responsive Operable Breast Cancer 1Genetic Diseases, Inborn 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Advanced Breast Cancer 1

Interventions

Trastuzumab 8Doxorubicin 8Exercise 6Cyclophosphamide 6Echocardiography 5Carvedilol 5Docetaxel 4Tablets 2Silymarin 2Radiotherapy 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Exercise Test 2Epirubicin 2Bisoprolol 2Atorvastatin 2Anthracyclines 2sacubitril and valsartan sodium hydrate drug combination 1nicotinamide-beta-riboside 1mitoquinone 1epicatechin gallate 1empagliflozin 1dapagliflozin 1candesartan 1Watchful Waiting 1Therapeutics 1Taxes 1Tamoxifen 1Social Determinants of Health 1Secondary Prevention 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cardiotoxicity × Tablets × Breast × Clear all
NCT05559164 2025-11-14

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Rutgers, The State University of New Jersey

Phase 2 Recruiting
60 enrolled
Breast

Breast Neoplasms, Cardiotoxicity

NCT04434404 2020-06-16

Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy

Horus University

Phase 4 Completed
83 enrolled
Breast

Breast Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡